Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lonza Group | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 38.60B | 58x | -1.41 | CHF 534 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.5% Upside | Upgrade to Pro+ | |
Lonza Group | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 38.60B | 58x | -1.41 | CHF 534 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.5% Upside | Upgrade to Pro+ | |
BACHEM HOLDING AG | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 4.43B | 38.9x | 2.6 | CHF 59 | 1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39.9% Upside | Upgrade to Pro+ | |
BB Biotech | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 2B | 15.9x | 0.11 | CHF 36.65 | 3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 1.94B | 15.9x | 0.11 | CHF 34.95 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Kuros Biosciences | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 809.70M | -70.5x | -2.98 | CHF 21.50 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Basilea Pharmaceutica AG | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 501.21M | -767.6x | 7.72 | CHF 41.50 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Idorsia | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 178.91M | -0.6x | -0.02 | CHF 0.98 | 19.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22% Upside | Upgrade to Pro+ | |
Newron Pharmaceuticals | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 173.96M | -9.3x | 0.58 | CHF 8.81 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Molecular Partners AG | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 171.04M | -2.4x | 0.72 | CHF 4.43 | 9.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Xlife Sciences | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 145.84M | 11.8x | 0.38 | CHF 25 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Relief Therapeutics | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 54.17M | -1.2x | -0.02 | CHF 4.40 | 4.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Addex Therapeutics Ltd | Switzerland | Healthcare | Biotechnology & Medical Research | CHF 6.49M | 1.2x | -0 | CHF 0.07 | 17.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |